London-based drugmaker Hikma Pharmaceuticals (LSE: HIK) has made two appointments in a signal of its intent to grow internationally.
The company was initially founded 40 years ago as a branded generics business focused on the Middle East and north Africa, though it has now grown into a global generic pharmaceuticals company with a London listing and annual revenues of $2 billion.
The new appointments are part of Hikma’s global growth strategy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze